1 Antimicrobial agents for the treatment of enteric 2 fever chronic carriage: A systematic review

3 Short title: Antimicrobial agents for the treatment of enteric fever
4 chronic carriage

5 McCann N^{1,2}, Scott P^{1,2}, Parry CM^{3,4,5}, Brown M^{1,6}

6

7 1. Hospital for Tropical Diseases, University College London Hospitals NHS
8 Foundation Trust, London, UK

9 2. UCL Faculty of Population Health Sciences, University College London
10 (UCL), London, UK

11 3. Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK

12 4. Alder Hey Children's NHS Foundation Trust. Liverpool, UK

13 5. Centre for Tropical Medicine and Global Health, University of Oxford, Oxford,
14 UK.

15 6. Clinical Research Dept, London School of Hygiene & Tropical Medicine

16

17

18

19

20 *Correspondence to:*

21 *Dr Naina McCann,*

22 Naina.mccann@nhs.net/zchaf30@ucl.ac.uk

23

24 **NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

Abstract

Background

Chronic carriage of *S. Typhi* or *S. Paratyphi* is an important source of enteric fever transmission. Existing guidance and treatment options for this condition are limited. This systematic review aims to assess the evidence concerning the efficacy of different antimicrobials in treating enteric fever chronic carriage.

Methods

We searched major bibliographic databases using relevant keywords between 1946 and September 2021. We included all interventional studies that included patients with confirmed enteric fever chronic carriage and deployed an antimicrobial that remains in clinical practice today. Case reports and case series of under 10 patients were excluded. Two reviewers screened abstracts, selected articles for final inclusion and quality-assessed the included studies for risk of bias. Extracted data was analysed, with pooling of data and eradication rates for each antimicrobial calculated. As only one randomised controlled trial was identified no meta-analysis was performed.

Results

Of the 593 papers identified by the initial search, a total of eight studies met the inclusion criteria and were included in the systematic review. Evidence was identified for the use of fluoroquinolones and amoxicillin/ampicillin in the treatment for enteric fever chronic carriage. Fluoroquinolones were superior to amoxicillin/ampicillin with 92% of patients eradicated after one antimicrobial

course compared to 68% ($p = 0.02$). The quality of included studies was poor, and all were carried out before 1990.

Conclusion

This review identified fluoroquinolones and amoxicillin as treatment options for enteric fever chronic carriage, with fluoroquinolones the more effective option. However, this evidence pre-dates rises in antimicrobial resistance in enteric fever and therefore the significance of these findings to today's practice is unclear. Further research is needed to investigate whether these antimicrobials remain appropriate treatment options or whether alternative interventions are more effective.

Author summary

There are more than 14 million cases of enteric fever every year globally. The rise of antimicrobial resistance against *S. Typhi* and *S. Paratyphi*, the pathogens causing enteric fever, has led to limited treatment options against this condition. Mechanisms to prevent infection are therefore becoming increasingly important. Public health measures and, more recently, the development and rollout of the typhoid conjugate vaccine, are going some way towards reducing transmission of this condition but identification and treatment of enteric fever chronic carriers has been neglected.

S. Typhi and *S. Paratyphi* are restricted to human hosts and transmitted via the ingestion of contaminated food or water. Chronic carriers, those who asymptotically excrete the pathogens in their stool following infection, play an important role in maintaining the reservoir of infection within humans. Identification and treatment of these carriers will be vital in further reducing transmission of enteric fever and ultimately eliminating this condition.

Here we review the evidence for antimicrobials in treating enteric fever chronic carriage. We identify evidence for fluoroquinolones and amoxicillin as treatment strategies but highlight large gaps in the literature on this subject, including a lack of evidence in the antimicrobial-resistant era of enteric fever.

Introduction

Enteric fever is a systemic febrile illness caused by infection with the Gram-negative bacteria *Salmonella enterica* subspecies serovars Typhi (*S. Typhi*) and Paratyphi A, B or C (*S. Paratyphi*). It causes significant morbidity and mortality globally, with approximately 14 million cases and 135,000 deaths per year, with the highest number of reported cases from South and South-East Asia(1).

Enteric fever is transmitted via the faecal-oral route via the ingestion of food or water contaminated with infected human faeces. Clinical illness usually occurs 7-14 days after exposure with a non-specific febrile illness. The majority of patients recover from acute enteric fever following an appropriate course of

96 antimicrobials. Around 10% of patients continue to excrete *S. Typhi* or *S.*
 97 *Paratyphi* in their stool for a few weeks in the convalescent period following
 98 recovery from acute infection with approximately 1-5% of patients continuing to
 99 excrete *S. Typhi* or *S. Paratyphi* in their stool for more than one year (2,3). This
 100 latter group are known as chronic carriers(4).

101

102 The pathogenesis of chronic carriage is not well understood. The gallbladder and
 103 biliary system appear to be the site of primary persistence of *S. Typhi* and *S.*
 104 *Paratyphi* in chronic carriers and indeed those with gallstones are more likely to
 105 become carriers (4–6).

106

107 *S. Typhi* and *S. Paratyphi* are human-restricted pathogens and therefore chronic
 108 carriage plays an important role in maintaining the reservoir of infection in
 109 humans. Asymptomatic chronic carriers unknowingly transmit the disease to
 110 others by faecal contamination of food and water. The first, and perhaps most
 111 famous example of this was Mary Mallon ('typhoid Mary') who worked as a chef
 112 in New York in the 1950s and infected at least 54 people as an asymptomatic
 113 carrier(3). Since then forensic epidemiology has demonstrated many more such
 114 cases, for example Mr N the Folkestone milker who infected over 200 people
 115 over a number of years via infected milk (7).

116

117 In addition to the public health risk of chronic carriage there is evidence that
 118 chronic carriage is associated with an increased individual risk of malignancy,
 119 particularly gallbladder cancer (8–10). A recent meta-analysis reported an

overall odds ratio of gallbladder cancer in *S. Typhi* carriers of 4.28 (95% CI: 1.84–9.96) (11).

The identification and treatment of chronic carriers therefore has both a significant public health and arguably individual benefit. There is currently limited evidence or guidance on how these chronic carriers should be treated. Furthermore, recent clinical reviews on the subject give differing advice on whether antimicrobials are an effective treatment option for chronic carriage treatment (12–14).

WHO enteric fever guidelines from 2003 suggest treatment options for enteric fever chronic carriage of amoxicillin, co-trimoxazole or ciprofloxacin (15). Over the last 30 years there have been significant changes in antimicrobial resistance patterns of *S. Typhi* and *S. Paratyphi*, with decreased susceptibility to fluoroquinolones (Fq) now almost universal in some areas of South Asia and increasing across sub-Saharan Africa (16–18). Multi-drug resistance (MDR), resistance to amoxicillin, co-trimoxazole, chloramphenicol, is also seen in around 40% of patients worldwide (16). A current outbreak of extensively-drug-resistant (XDR) enteric fever in Pakistan has highlighted the limited antimicrobial treatment options available for acute enteric fever in this setting. The options for antimicrobial treatment of enteric fever chronic carriers in the era of drug-resistance are unknown.

The aim of this systematic review is to review the existing evidence of efficacy of antimicrobials in treating enteric fever chronic carriage. By doing so we hope to

review existing knowledge and highlight areas for ongoing research and review.

Methods

The reporting of this systematic review was guided by the standards of the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement (19). A search of PROSPERO database performed did not reveal any existing similar protocols. The protocol for this review was not registered but can be found in supplementary material (S3)

Search strategy and selection criteria

A systematic search through MEDLINE, EMBASE and Web of Science from 1946 was initially performed on the 1st February 2021. The terms searched were (“typhoid” OR “paratyphoid” OR “salmonella typhi” OR “salmonella paratyphi” OR “enteric fever”) AND (“chronic carriage” OR “disease carrier” OR “carrier state” OR “typhoid carrier” OR “paratyphoid carrier” AND (“antibiotic” OR “antibacterial” OR “antibacterial treatment” OR “antibiotic treatment” OR “antibacterial agent” OR “antibiotic agent” OR names of individual antibiotics). The full list of search terms is listed in the supplementary information (S1). No language restrictions were included in the initial search. Reference lists and bibliographies of selected articles were also searched. A search for unpublished literature was not performed.

A repeat search of the same terms was performed in September 2021 to check for any additional studies that could be included prior to publication. All new articles identified that been published since the prior search date were reviewed by two independent reviewers.

We included studies that met the following criteria:

- 1) Baseline population of adults with confirmed enteric fever chronic carriage
- 2) Intervention of an antimicrobial course
- 3) Outcomes of stool clearance measured as defined by authors of each included study

We did not include studies that assessed an antimicrobial that is no longer in clinical use today, for example sulphathiazole. Case reports and case series of under 10 cases were excluded to minimize study bias. If studies included participants with non-typhoidal salmonella (NTS) chronic carriage in addition to patients with enteric fever chronic carriage these studies were individually reviewed to assess whether they included 10 or more patients with enteric fever chronic carriage and, if they met other inclusion criteria, they were included. Studies that combined an antimicrobial treatment intervention with another intervention (e.g. cholecystectomy) were only included if they had an intervention arm that included antimicrobials alone and this was made up of $\geq$ 10 patients.

If journal articles were not available online, we requested print versions through store requests in our academic institution. Articles were excluded if we could not access a full-text version for review. Two independent researchers screened titles and abstracts and reviewed full text articles for inclusion with any disagreements resolved by consensus.

Quality of studies

Two independent reviewers evaluated the study quality with any disagreements resolved by consensus. Quality assessment was performed using the National Heart, Lung and Blood Institute quality assessment tools (20). Each study was given an overall rating of good, fair or poor.

Data extraction

Data extraction was performed using a standardized data extraction form. Data was collected on publication year, study country, study design, participant characteristics including number of patients with gallstones, number of participants given intervention, intervention type including dose and duration, stool culture result at follow-up and side effects of intervention.

Data analysis

For each included study the proportion of those chronic carriers that eradicated the pathogen (eradication proportion) was calculated (i.e., the number of participants culture negative for *S. Typhi* or *S. Paratyphi* after an antimicrobial intervention divided by the total number of participants in the study).

216
217 For those that had a control population we calculated the eradication proportion
218 in this population. Data was synthesized for studies using the same antimicrobial
219 intervention and overall eradication proportions presented. The main outcome
220 measure was eradication proportion after one course of antimicrobials. As some
221 studies re-treated their patients' multiple times, we also calculated eradication
222 proportion per antimicrobial course. Other data synthesised for each
223 antimicrobial intervention included intervention characterises and side effects of
224 antimicrobial use. Results were presented in tabular format comparing
225 antimicrobial intervention. Categorical variables were compared using Fishers
226 exact test. Data was collated in Microsoft Excel and analysed in RStudio version
227 1.4.1103.

228

229

230 **Results**

231

232 **Flow of included studies**

233 The initial search strategy identified 579 papers. The abstracts and titles were
234 reviewed and after applying inclusion and exclusion criteria 26 papers were
235 identified for full-text evaluation. Of these a further 18 were excluded for reasons
236 shown in the PRISMA flow-chart in Figure 1, leaving 8 articles which met our
237 inclusion criteria. Full-text manuscripts could not be accessed in 7 cases; all but
238 one of these were published in non-English language journals (3 German, 1
239 Polish, 1 Russian, 1 Japanese). Of these 3 were published before 1960 and the

remaining 4 were published before 1980. A further search using the same terms was performed in September 2021 which identified a further 14 papers, none of which were deemed eligible for inclusion.

Figure 1. Preferred Reporting Items for Systematic Reviews (PRISMA) flow diagram of the study selection process

Study characteristics

Study characteristics of all included studies are summarised in Table 1. Only one used a blinded randomised-control trial (RCT) design. The remaining seven studies used an open, pre- post design method with no controls, comparing stool culture (outcome measure) in participants before and after treatment.

Included studies were carried out between 1966 and 1988, with no studies included from the last 30 years. The majority of studies were carried out in the USA (n= 4) with the remaining papers conducted in Chile (n = 1), Peru (n = 1), Italy (n= 1) and Israel (n = 1).

Table 1. Summary of included studies

Study author and references	Country	Year	Journal published	Planned intervention, drug, dose and duration	Study design	Outcomes
--------------------------------	---------	------	----------------------	---	--------------	----------

Ferreccio et al (21)	Chile	1988	Journal of Infectious Diseases	Ciprofloxacin PO 750mg BD, 28 days	Open pre- and post- trial, no control	3 s 3,6 tre
Gotuzzo et al(22)	Peru	1988	Journal of Infectious Diseases	Norfloxacin PO 400mg BD, 28 days	Double-blind randomised- controlled trial, followed by open trial	St 1,2
Phillips et al (23)	USA	1971	Journal of American Medical Association	Ampicillin PO 1g QDS, 90 days	Open pre- and post- trial, no control	St mi tre
Simon et al (24)	USA	1966	New England Journal of Medicine	Ampicillin PO 75- 100mg/kg/day for 28 days	Open pre- and post- trial, no control	St fir fol tin 7 r
Nolan et al (25)	USA	1978	Journal of American Medical Association	Amoxicillin PO 2g TDS for 28 days	Open pre- and post- trial, no control	St me
Dinbar et al (26)	Israel	1969	American Journal of Medicine	Ampicillin PO 5.25mg/day for 10- 40 days	Open, multi-arm pre- and post- trial, no control	St mi tre
Kaye et al (27)	USA	1967	Annals of the New York Academy of Science	Ampicillin PO 1.5mg QDS + probenecid 0.5g QDS, 42 days	Open pre- and post- trial, no control	St de me

Scioli et al (28)	Italy	1970	Journal of Infectious Diseases	Ampicillin IV 1g TDS, 15 days	Open pre- and post- trial, no control	St for on of
-------------------	-------	------	--------------------------------	-------------------------------	---------------------------------------	--------------

259

260

261 Inclusion criteria for almost all the studies was presence of *S. Typhi* or *S.*
262 *Paratyphi* in the stool or bile for greater than 12 months. One study necessitated
263 prior history of acute enteric fever (29) and one study included two patients who
264 had positive stool cultures with an elevated Vi antibody level, without need for
265 repeated positive cultures of > 1 year (30). One study mentioned that included
266 patients had been previously treated for chronic carriage (28) but others did not
267 specify this. Length of chronic carriage varied between participants within
268 studies, with the longest carrier state being 39 years. Two studies excluded those
269 with serious underlying health conditions and patients with penicillin allergies
270 (29,31). Exclusion criteria were not well defined in the other studies.

271

272 The age range of included participants was broad, including adults from 18-81
273 years. One study included one child aged 7 years old with the results not
274 separated from the 14 adults in the study(32). After discussion between
275 reviewers this study was included. The majority of participants in the studies
276 were female which correlates with prior knowledge that females are more likely
277 to be carriers (33).

278

Most of the studies investigated participants for underlying gallstones before enrolment in the study using ultrasound or cholangiography or X-ray. However, in some patients the biliary tract was not well visualised and two studies did not investigate for underlying gallstones prior to enrolment (30,34). These patients were categorised in a third category ‘gallstone status unknown’.

Study intervention

The intervention drug was a fluoroquinolone (Fq) in two studies: norfloxacin was used in one and ciprofloxacin in the other. Four of the studies used ampicillin alone as the intervention, one study used amoxicillin and one used ampicillin with probenecid. One of the ampicillin studies used intravenous administration but the rest of the studies used oral administration. Dosing varied between the different studies (see Table 1). One study also included separate arms of the study with patients undergoing cholecystectomy and cholecystectomy in combination with ampicillin treatment (26). In this study six of the patients undergoing antimicrobial treatment alone had previously undergone cholecystectomy in the other arm of the study. These were included as they were confirmed to still be chronic carriers 1 year post cholecystectomy and prior to enrolment in the antimicrobial arm.

Quality assessment

Overall methodological quality of included studies was poor (see Table 1). There was only one randomised and blinded study, with the majority of studies designed as pre- and post-studies without a control.

In the RCT study, the outcomes were inconsistently reported with the summary table showing no cases of eradication in the placebo group but the text reporting that one patient this arm did have negative stool cultures at follow-up (indicating spontaneous cure). Furthermore, 13 patients were enrolled in the norfloxacin arm but only 12 patients included in the final analysis with no intention-to-treat analysis performed. No relative risk or odds ratio was calculated.

The remainder of the studies were open, pre- and post- studies without controls. Overall inclusion criteria were well defined, but studies did not clearly state how patients were enrolled.

Interventions were generally well defined but often not consistent across participants, with some studies changing dosing regimens during the study period and one study using multiple interventions on participants (26). All studies clearly defined the outcome measure, and this was measured before and after intervention and at repeated intervals for adequate follow-up periods after intervention. Loss to follow-up in the included studies was small (less than 20% in all). None of the studies mentioned a power calculation and numbers of participants were small in all studies. Minimal statistical analysis was performed.

A meta-analysis was not performed as there was only one RCT identified.

Outcomes by antimicrobial group

Fluoroquinolones

327 Two studies assessed Fq as a treatment option for *S. Typhi* chronic carriage, and
 328 no studies assessed Fq as a treatment option for *S. Paratyphi* chronic carriage. In
 329 the *S. Typhi* studies a total of 25 patients received an intervention course
 330 (29,35). The norfloxacin study was an RCT, comparing 28-days of 400mg BD
 331 norfloxacin to placebo. The ciprofloxacin study was a pre-post study
 332 investigating the effect of a 28-day course of 750mg BD ciprofloxacin. All patients
 333 had *S. Typhi* chronic carriage, 44% of whom were known to have gallstones
 334 (although this was not specifically looked for in one of the studies). Both Fq
 335 studies showed an eradication proportion of 92% following a single 28-day
 336 treatment course. These two studies are summarised in Table 2.

337

338 **Table 2. Summary of results from studies using fluoroquinolone antibiotics**
 339 **to treat *S. Typhi* chronic carriage**

Intervention given	Groups			
	No n	Fluoroquinolones o	Penicillins o	Combined interventions o
Participant characteristics				
Total no of participants, n	13	12	12	25
With gallstones, n (%)	9 (69)	9 (75)	2 (17)	11 (44)
Without gallstones, n (%)	4 (31)	3 (25)	0	4 (16)
Unknown gallstone status, n (%)	0 (0)	0	10 (75)	10 (36)
Demographics				
Age, mean	36	35	31	34
Age, range	18-58	12-67	20-51	18-67
Female, n (%)	6 (46)	11 (92)	10 (83)	16 (64)
Microbiological characteristics				
S. Typhi, n (%)	13 (100)	12 (100)	12 (100)	25 (100)
MIC to intervention drug, range (ug/mL)	0.06 – 0.5	0.06-0.5	0.0156-0.0078	0.0078-0.5
Intervention				
Administration method	PO	PO	PO	
Total daily dose, mean (mg)	800	NA	1500	
Total duration, mean (days)	28	28	25	
Duration range, (days)	28	28	10-28	
Outcomes – eradication				
Minimum follow-up (months)	3	3	12	3
Total no of patients included in analysis ¹ , n	12	12	12	24
Total no patients eradicated at end of follow-up, n (%)	11 (92)	1 (8)	11 (92)	22 (92)
Eradicated in those with gallstones, n (%)	7 (88)	1 (8)	2 (100)	9 (82)

<i>Eradicated in those without gallstones, n (%)</i>	4 (100)	0 (0)	0 (0)	4 (100)
<i>Eradicated in those with unknown gallstone status, n (%)</i>	0 (0)	0 (0)	9 (90)	9 (90)
Outcomes – side effects				
<i>Total side effects, n (%)</i>	1 (8)	3 (25)	5 (41)	6 (25)
<i>Diarrhoea, n (%)</i>	0	0	0	0
<i>Rash, n (%)</i>	0	0	1 (8)	1 (4)
<i>Other, n (%)</i>	1 (8)	3 (25)	4 (33)	5 (21)
Total no of antibiotic courses given², n	23	12	12	35
<i>No of antibiotic courses resulting in successful eradication, n (%)</i>	18 (78)	1 (8)	11 (90)	29 (83)

340 1 – One patient was excluded from norfloxacin analysis in Gottuzo paper due poor adherence
341 2 – In Gotuzzo paper 10 placebo patients were re-treated with norfloxacin openly taking the total
342 number of treatment courses given in this paper to 23.

344 In the RCT the norfloxacin group had a higher proportion of *S. Typhi* eradication
345 than the control group (92% vs 8%, $p < 0.001$).

347 **Effect of gallstones on eradication**

348 Patients in the ciprofloxacin study were not routinely screened for biliary
349 disease before enrolment in the study, however two patients were known to
350 have gallstones. In the norfloxacin study patients underwent oral
351 cholecystogram, IV cholangiography or gallbladder ultrasound before enrolment.

353 Eradication proportions were 100% in those without gallstones, 89% in those
354 with unknown gallstone status and 82% in those with known gallstones.

356 **Side effects**

357 Side effects were seen in a quarter of patients. In the ciprofloxacin study two
358 patients stopped treatment early due to side effects (haemoglobin drop and

urticarial rash). Of note, three other patients in this study had a haemoglobin drop that were attributed to ciprofloxacin therapy. Norfloxacin was relatively well-tolerated in the other study with only one patient reporting a rash, although these are not further explored in this paper.

Effect of repeated courses

In the norfloxacin study patients initially treated with placebo were then retreated with norfloxacin. This group had a slightly lower eradication proportion of 70%, lowering the overall eradication proportion to 83% per antibiotic course overall.

Ampicillin/amoxicillin

The remaining six studies identified assessed amoxicillin or ampicillin (amox/amp) use. The results of these are summarized in Table 3.

Table 3. Summary of results from studies using amoxicillin or ampicillin as a treatment for *S. Typhi* or *S. Paratyphi* chronic carriage

Participant characteristics					
<i>Total no of participants</i>	12	15	15	16	24
<i>With gallstones, n (%)</i>	0	5 (33)	4 (27)	3 (12)	12 (50)
<i>Without gallstones, n (%)</i>	0	10 (66)	11 (73)	7 (87)	7 (25)
<i>Unknown gallstone status, n (%)</i>	12 (100)	0 (0)	0 (0)	6 (38)	5 (21)
<i>Known to have had cholecystectomy, n (%)</i>	0 (0)	1 (7)	0	7 (44)	1 (4)
Demographics					
<i>Age, mean</i>	57	44	65	53	59
<i>Age, range</i>	23-81	7-62	48-77	36-67	33-83
<i>Female, n (%)</i>	7 (58)	10 (66)	13 (87)	7 (44)	18 (75)
Microbiological characteristics					
<i>S. Typhi, n (%)</i>	12 (100)	15 (100)	12 (100)	15 (94)	24 (100)
<i>MIC to intervention drug, range (ug/mL)</i>	NA	<1 - 2	< 1	0.5-2.5	NA
Intervention characteristics					
<i>Intervention name</i>	Ampicillin	Ampicillin	Amoxicillin	Ampicillin	Ampicillin
<i>Administration method</i>	PO	PO	PO	PO	PO
<i>Intended daily regimen</i>	1g QDS	75- 100mg/kg	2g TDS	1.25g QDS	1.5g QDS
<i>Intended duration (day)</i>	90	28	28	10-40	42
<i>Addition of probenecid</i>	No	No	No	No	Yes
Dosing details of initial course given					
<i>Total daily dose, mean (g)</i>	4	4	5.2	5.1	5.5
<i>Total course duration, mean (days)</i>	90	28	28	25	36
<i>Total dose taken during course, mean (g)</i>	360	112	146	128	198
Outcomes – eradication					
<i>Minimum follow-up (months)</i>	18	7	12	12	12
<i>Total no patients eradicated after initial course, n (%)</i>	9 (75)	13 (87)	11 (73)	7 (44)	9 (38)

<i>Eradicated in those with gallstones, n (%)</i>	0 (0)	4 (80)	3 (75)	0 (0)	4 (33)
<i>Eradicated in those without gallstones, n (%)</i>	0 (0)	8 (89)	9 (82)	4 (57)	5 (71)
<i>Eradicated in those with unknown gallstone status, n (%)</i>	9 (75)	0 (0)	0 (0)	3 (50)	0 (0)
<i>Eradicated in those with known cholecystectomy, n (%)</i>	0 (0)	1 (100)	0 (0)	3 (43)	0 (0)
<i>Total no of patients eradicated at end of follow-up, n (%)</i>	9 (75)	13 (87)	11 (92)	9 (56)	12 (50)
<i>Total no of antibiotic courses given, n</i>	12	17	15	21	31
<i>No of antibiotic courses resulting in successful eradication (%)</i>	9 (75)	13 (76)	11 (73)	9 (43)	12 (39)
<i>Outcomes – side effects</i>					
<i>Total side effects, n (%)</i>	8 (67)	10 (67)	7 (47)	NA	5 (21)
<i>Diarrhoea, n (%)</i>	5 (42)	8 (53)	3 (20)		1 (4)
<i>Rash, n (%)</i>	5 (42)	6 (40)	2 (13)		5 (21)
<i>Anaphylaxis</i>	1 (9)				
<i>Other, n (%)</i>	0 (0)	2 (20)	3 (20)		

376

377

378

379 Overall, 101 patients were given a total of 115 courses of amox/amp (either PO

380 or IV). Most of these patients were female and 28% had confirmed gallstones.

381 Only one patient had *S. Paratyphi*. The dosing regimens were relatively high with

382 the mean daily dose of amoxicillin 4.5g/day but this varied significantly between

383 studies (range 3-5.5g/day). The mean duration of treatment was 37 days but

384 again this was highly variable between regimens (range 15-90 days).

385

386 The overall eradication proportion after a single course of amox/amp was 68%

387 but again, this was highly variable between studies (range 38-100%).

388

389 ***Effect of administration method on eradication***

There was only one study looking at the effect of IV ampicillin on chronic carriage eradication proportion(28). The mean daily dose and total cumulative dose of IV ampicillin used in this study were much lower than those used in the oral studies (3g vs a mean of 4.7g for the oral studies). However, the eradication proportion in this study was notably higher when compared to the oral ampicillin studies (100% vs 60%, $p < 0.01$) with no failures described in the IV arm.

Effect of dosing regimen and duration on eradication

The total daily dose of amox/amp varied between 4 and 5.5g for the studies using oral intervention, with the total drug given over the duration of the course between 112g to 360g.

Overall comparisons between dosing regimen and duration are not possible as different studies used widely variable dosing regimens and durations, often not standardised within their own study population. Therefore, individual regimens within studies were examined more closely to investigate for possible associations of dosing or duration with outcome.

In the Nolan et al study (36) two different dosing regimens of amoxicillin were given. For those that tolerated it ($n = 10$) a dosing regimen of 2g of oral ampicillin was administered three times daily (total daily dose of 6g) which had a 90% success after one course of 28 days. In those who did not tolerate the higher dose ($n = 5$) a lower dosing regimen of 1g oral ampicillin three times a day

(total daily dose of 3 grams) was started. This regimen only had a 40% eradication proportion after 28 days, but the numbers were very small.

Similarly, in Phillips et al (23) those who completed the full dosing schedule had a 90% eradication proportion whereas those who were unable to complete it had a 0% eradication proportion, although these numbers are small and the exact dosing regimens are not fully described in the paper.

In Dinbar et al (26) the initial course length was 10 days with a total of 52g of ampicillin given over this time. This regimen had an eradication proportion of 38%. Over the period of the study the dose of ampicillin was increased to 200g given over 40 days. The eradication proportion of this regimen was 57%. There was no evidence to support a difference in eradication proportions between dosing regimens ($p = 0.61$).

The Kaye study was the only study to use probenecid in addition to ampicillin. Eradication proportions were lower in this study when compared to the other studies where probenecid was not used (38% vs 76%).

Overall, we are unable to draw any firm conclusions from this data whether dose or duration of this intervention effects eradication proportion although there is a slight suggestion that higher daily dosing and intravenous dosing may be slightly more effective.

Effect of gallstones on eradication

All studies investigated for prior presence of gallstones except Phillips et al. The eradication proportion was lower in those with gallstones compared to those without gallstones (55% vs 79%, $p = 0.039$). Those with unknown gallstone status had an eradication proportion of 62%, whereas those with a past cholecystectomy only had an eradication proportion of 50%, although the numbers in this group are small.

Effect of repeated courses on eradication

After failing an initial course of therapy some patients were re-treated with a second or third course. In Kaye et al six patients who failed an initial course were re-treated with further courses of ampicillin. Of these only two were successfully eradicated (27). In Dinbar et al four patients who initially failed therapy were successfully treated with higher dosing regimens of ampicillin (26). In Simon et al one patient was re-treated twice with prolonged six-week courses of ampicillin which did not result in eradication (24). In total, of the 11 patients that were re-treated, the eradication proportion was only 36%.

Side effects

A third of patients in the ampicillin studies suffered side effects from their therapy. Rash and diarrhoea were the most common side effects and in two studies this resulted in a modification to therapy (31,34). In the IV amoxicillin trial side effects were minimal. However, side effects were not routinely reported across the studies.

Comparing antimicrobial groups

Fluoroquinolones have a higher overall eradication proportion than amox/amp (92% vs 68%, $p = 0.02$). In those with gallstones the eradication proportion remains higher in those taking a Fq compared to those taking amox/amp but this is not significant (82% vs 55%, $p = 0.16$).

Discussion

This is the first systematic review on the efficacy of antimicrobial agents for treatment of enteric fever chronic carriage. A total of 126 participants in 8 studies were included in this review and two intervention groups were identified: Fq and amox/amp. Overall eradication proportion was higher in the Fq compared to the amox/amp group (92% vs 68%, $p = 0.02$), but eradication proportions varied highly across the included studies.

These findings are consistent with the limited existing guidelines available on treatment of chronic carriage. As previously stated, the only available guidance for treatment of chronic carriers is from the WHO 2003 guidelines which suggests a quinolone, amoxicillin or co-trimoxazole (12,15). In this review we have not identified any specific evidence for use of co-trimoxazole. During the screening process we did identify literature investigating the use of co-trimoxazole in addition to other antimicrobials such as chloramphenicol, kanamycin and penicillin (37–43). None of these studies met the criteria for inclusion in this study, again highlighting the poor quality of available evidence

on this subject. Most of these studies were case reports, small case series or did not report on necessary outcome data.

The findings of this systematic review should be interpreted with caution. Firstly, the overall quality of the included studies was poor, with only one RCT included. The remainder of the studies were case series or pre- and post- studies with no control group and no blinding, which allowed for significant bias. Furthermore, in most studies it was unclear how patients had been identified for participation. Interventions were non-consistent within and across studies and the total number of included patients is small, limiting statistical analysis and overall conclusions.

Secondly, almost all the patients included in this study had *S. Typhi* chronic carriage and therefore limited conclusions can be made about the effectiveness of these antimicrobials on *S. Paratyphi* chronic carriage. With the rollout of the typhoid conjugate vaccine and the likely associated decrease in incidence of *S. Typhi*, the incidence of *S. Paratyphi* may start to rise (44). Given there is currently no licensed vaccine for *S. Paratyphi* the role of treatment of carriers of this condition may become increasingly important in reducing enteric fever transmission and disease. This review identifies current large gaps in the evidence base for the treatment of this neglected condition.

Thirdly, and perhaps most importantly, the included trials were all carried out prior to widespread antimicrobial resistance of enteric fever. There are no studies that have been carried out to assess treatment options for enteric fever

chronic carriage in patients with multi-drug resistant (MDR), Fq-resistant, or indeed extensively-drug-resistant enteric fever. This data is therefore inadequate to inform decisions regarding antimicrobial treatment of chronic carriage in the modern-day era of drug-resistant enteric fever.

Further research needs to be done to understand and improve treatment options for enteric fever chronic carriers today. The first barrier to investigating treatment interventions on chronic carriers is the accurate identification of chronic carriers from the population. In the trials included in this study, regular stool cultures were used to identify carriers over many years. This is logistically challenging and not suitable for large-scale screening today, particularly in low-resource endemic areas. Furthermore, as stool shedding is intermittent, the sensitivity is low (45). Molecular and serological strategies to identify carriers have been explored but do not perform well, particularly in endemic settings (46,47). New methods to identify carriers such as antigen-specific antibodies and biomarkers show promise but need further exploration (48,49).

Once carriers can be accurately identified, further work is needed to investigate the effect of different interventions on this population. There is limited data on the antimicrobial susceptibility of chronic carriage isolates and whether they harbour similar resistance profiles to acute enteric fever strains. A study from 2012 in Nepal looking at *S. Typhi* and *S. Paratyphi* isolates identified from cholecystectomies found lower rates of antimicrobial resistance in these strains, compared to acute enteric fever isolates in the same area (50). This suggests that chronic carriage strains may originate from older, drug-susceptible strains for

which Fq and Amp may still be effective. Previous work looking at the genetic diversity of *S. Typhi* has suggested this may be due to two different evolutionary methods within the population structure of *S. Typhi* (51).

Even if chronic carriage isolates do show reduced susceptibility to ciprofloxacin, the excellent bile penetration of this antimicrobial (reaching 2500-4500% of plasma concentrations in the bile(52)), may be sufficient to overcome the relatively low minimum inhibitory concentration (MIC) (e.g. with MIC ≤ 1) isolates, although there is no patient outcome data to support this.

Alternative antimicrobials that have not been identified in this review may also be effective in treating chronic carriage. Azithromycin is currently used to treat uncomplicated enteric fever worldwide with good efficacy (53) but no studies have examined the efficacy of azithromycin on enteric fever chronic carriage. Azithromycin has good bile penetration (52) and a single case report suggests it may eradicate non-typhoidal *Salmonella* carriage (54). It therefore may be a good intervention for enteric fever chronic carriage treatment and is currently the preferred treatment for Fq resistant chronic carriage eradication in the UK; post-treatment monitoring will be used to assess outcome.

It is well understood that the gallbladder is an important niche for the persistence of *S. Typhi* and *S. Paratyphi* and the development of carriage (12,55). Accordingly, cholecystectomy has been used as treatment for chronic carriage in the past (26,56,57). In addition to carrying a significant anaesthetic and surgical risk this intervention does not guarantee elimination of the carrier state, with

success rates reported between 70-90%. Studies in this review also identify multiple patients identified as carriers who had already undergone a prior cholecystectomy. Hence, it is likely that there are other foci of infection outside the gallbladder that also play an important role in *S. Typhi* and *S. Paratyphi* persistence and carriage, for example the biliary tree, liver or lymph nodes(58).

Recently, murine models have shown that biofilm formation, on gallbladder epithelium and cholesterol-rich gallstones, may play an important role in the development of carriage and protect against antimicrobial treatment (55,59–63). Prior guidance similarly states that carriers with underlying gallstones are unlikely to be eradicated with antimicrobials alone (12,15). In contrast, this review shows relatively good eradication proportions in those with gallstones, particularly when Fq treatment was used, albeit lower than those without gallstones. Furthermore, many of the identified carriers in this review were not found to have gallstones, despite thorough investigation. It is evident that further work is required to better understand the pathophysiology of chronic carriage to allow the development of targeted interventions.

This review was limited by the high risk of bias in all included studies. Many studies showed selection bias with undefined selection of participants and exclusion of certain groups. The participants may not be a true representative of the carrier population. Minimal data was reported from all studies with very little statistical analysis performed. Particularly, the presence of gallstones was not investigated or reported in all studies meaning conclusions on whether gallstones affect the effect of antimicrobial eradication are uncertain.

587

588 Side effects of medications were also poorly reported across studies. Some
589 adverse events were linked to the intervention without obvious causality e.g.
590 ciprofloxacin causing haemoglobin drop, when this is not a known common side
591 effect. Furthermore, associations of Fq therapy that were not recognised when
592 these studies took place, for example tendinopathy and aneurysm rupture, may
593 have been under-reported. The recent realisation of potential significant side
594 effects of Fq use has also led to restrictions in their use and they may no longer
595 be suitable to treat patients with chronic carriage, again highlighting the need for
596 alternative treatment strategies (64,65).

597

598 In this review we excluded case reports or case series of less than 10 patients in
599 attempt to reduce bias but in doing so may have excluded studies with additional
600 interventions. Furthermore, the evidence relating to this topic is almost all more
601 than 30 years old and some full-text articles were not able to be accessed, some
602 of which may have otherwise been included in the final review. The strengths of
603 our study include a comprehensive search strategy, the use of two independent
604 reviewers throughout the process and the use of well-defined data extraction
605 and quality assessment tools.

606

607 In conclusion, this review identifies evidence for fluoroquinolones and
608 amoxicillin/ampicillin as antimicrobial interventions for treatment of enteric
609 fever chronic carriage. Fluoroquinolones are the most effective antimicrobial
610 intervention and should be recommended for first-line treatment of chronic
611 carriage where the isolate is susceptible, given the lack of evidence for any other

interventions. There is insufficient evidence to recommend empiric use of fluoroquinolones or amoxicillin/ampicillin for enteric fever chronic carriage today, due to significant changes in antimicrobial resistance over the last 30 years. Updated evidence on this neglected topic is required and should be a vital component of global eradication strategies for enteric fever going forward.

References

1. Stanaway JD, Reiner RC, Blacker BF, Goldberg EM, Khalil IA, Troeger CE, et al. The global burden of typhoid and paratyphoid fevers: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet Infect Dis* [Internet]. 2019 Apr 1 [cited 2021 Mar 17];19(4):369–81. Available from: <http://dx.doi.org/10.1016/>
2. T.M. V. Temporary and chronic carriers of *Salmonella typhi* and *Salmonella paratyphi* B. *J Hyg (Lond)* [Internet]. 1948;(3):252–61. Available from: <http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emcl1&N=EWS=N&AN=280592805>
3. Gonzalez-Escobedo G, Marshall JM, Gunn JS. Chronic and acute infection of the gall bladder by *Salmonella Typhi*: Understanding the carrier state. *Nat Rev Microbiol*. 2011;
4. Levine MM, Black RE, Lanata C. Precise estimation of the numbers of chronic carriers of *salmonella typhi* in Santiago, Chile, an endemic area. *J Infect Dis*. 1982;
5. Vogelsang TM, Bøe J. Temporary and chronic carriers of *Salmonella typhi* and *Salmonella paratyphi* B. *J Hyg (Lond)*. 1948;
6. Ames WR, Saphir W, Baer WH, Plotke F. Treatment of typhoid carriers. *J Am Med Assoc*. 1942;119:582.
7. Mortimer PP. Mr N the milker, and Dr Koch's concept of the healthy carrier. Vol. 353, *Lancet*. Elsevier; 1999. p. 1354–6.
8. Caygill CPJ, Hill MJ, Braddick M, Sharp JCM. Cancer mortality in chronic typhoid and paratyphoid carriers. *Lancet*. 1994;
9. Nath G, Singh H, Shukla VK. Chronic typhoid carriage and carcinoma of the gallbladder. *European Journal of Cancer Prevention*. 1997.
10. Dutta U, Garg PK, Kumar R, Tandon RK. Typhoid carriers among patients with gallstones are at increased risk for carcinoma of the gallbladder. *Am J Gastroenterol*. 2000;
11. Nagaraja V, Eslick GD. Systematic review with meta-analysis: The relationship between chronic *Salmonella typhi* carrier status and gallbladder cancer. *Alimentary Pharmacology and Therapeutics*. 2014.
12. Gunn JS, Marshall JM, Baker S, Dongol S, Charles RC, Ryan ET. *Salmonella*

- 653 chronic carriage: Epidemiology, diagnosis, and gallbladder persistence
654 [Internet]. Vol. 22, Trends in Microbiology. Elsevier Ltd; 2014 [cited 2021
655 Mar 17]. p. 648–55. Available from: /pmc/articles/PMC4252485/
656 13. Gal-Mor O. Persistent infection and long-term carriage of typhoidal and
657 nontyphoidal salmonellae. Clinical Microbiology Reviews. 2019.
658 14. Parry CM, Hein TT, Dougan G, White NJ, Farrar JJ. Typhoid fever. New
659 England Journal of Medicine. 2002.
660 15. World Health Organization WHO Background document: The diagnosis,
661 treatment and prevention of typhoid fever Communicable Disease
662 Surveillance and Response Vaccines and Biologicals [Internet]. 2003 [cited
663 2021 Feb 23]. Available from: www.who.int/vaccines-documents/
664 16. Browne AJ, Kashef Hamadani BH, Kumaran EAP, Rao P, Longbottom J,
665 Harriss E, et al. Drug-resistant enteric fever worldwide, 1990 to 2018: A
666 systematic review and meta-analysis. BMC Med [Internet]. 2020 Jan 3
667 [cited 2021 Mar 17];18(1):1–22. Available from:
668 <https://doi.org/10.1186/s12916-019-1443-1>
669 17. C. B. Screening, phylogenetic analysis and antibiotic sensitivity pattern of
670 Salmonella enterica serovar Typhi isolates from typhoid asymptomatic
671 carriers. Asian Pac J Trop Med [Internet]. 2011;4(10):769–72. Available
672 from:
673 [http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed12&](http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed12&NEWS=N&AN=362795595)
674 [NEWS=N&AN=362795595](http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed12&NEWS=N&AN=362795595)
675 18. Qamar FN, Yousafzai MT, Sultana S, Baig A, Shakoor S, Hirani F, et al. A
676 Retrospective Study of Laboratory-Based Enteric Fever Surveillance,
677 Pakistan, 2012–2014. J Infect Dis [Internet]. 2018 Nov 10 [cited 2021 Mar
678 17];218(suppl_4):S201–5. Available from:
679 https://academic.oup.com/jid/article/218/suppl_4/S201/5060309
680 19. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et
681 al. The PRISMA 2020 statement: An updated guideline for reporting
682 systematic reviews. The BMJ. 2021.
683 20. Study Quality Assessment Tools | NHLBI, NIH [Internet]. [cited 2021 Mar
684 29]. Available from: [https://www.nhlbi.nih.gov/health-topics/study-](https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools)
685 [quality-assessment-tools](https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools)
686 21. C. F, J.G. MJ, C. V, I. P, V. S, G.L. D, et al. Efficacy of ciprofloxacin in the
687 treatment of chronic typhoid carriers. J Infect Dis [Internet].
688 1988;157(6):1235–9. Available from:
689 [http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed4&N](http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed4&NEWS=N&AN=18164989)
690 [EWS=N&AN=18164989](http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed4&NEWS=N&AN=18164989)
691 22. E. G, J.G. G, L. B, J.C. P, C. C, J. L, et al. Use of norfloxacin to treat chronic
692 typhoid carriers. J Infect Dis [Internet]. 1988;157(6):1221–5. Available
693 from:
694 [http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed4&N](http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed4&NEWS=N&AN=18164987)
695 [EWS=N&AN=18164987](http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed4&NEWS=N&AN=18164987)
696 23. Treatment of chronic typhoid carriers with ampicillin. JAMA [Internet].
697 1971;217(7):913–5. Available from:
698 [http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed1&N](http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed1&NEWS=N&AN=91440054)
699 [EWS=N&AN=91440054](http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed1&NEWS=N&AN=91440054)
700 24. Simon HJ, Miller RC. Ampicillin in the Treatment of Chronic Typhoid
701 Carriers. N Engl J Med. 1966;

25. NOLAN CM, ROSENFELD J. ANTIBIOTIC SUSCEPTIBILITY OF SALMONELLA-TYPHI FROM CHRONIC ENTERIC CARRIERS. *Curr Ther Res Exp.* 1977;21(5):736–40.
26. Dinbar A, Altmann G, Tulcinsky DB. The treatment of chronic biliary Salmonella carriers. *Am J Med.* 1969;
27. Kaye D, Merselis JGJ, Connolly S, Hook EW. Treatment of chronic enteric carriers of Salmonella typhosa with ampicillin. *Ann N Y Acad Sci* [Internet]. 1967;145(2):429–35. Available from: <http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med1&NEWS=N&AN=5284273>
28. Scioli C, Fiorentino F, Sasso G. Treatment of Salmonella typhi carriers with intravenous ampicillin. *J Infect Dis* [Internet]. 1972;125(2):170–3. Available from: <http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med1&NEWS=N&AN=5007553>
29. Gotuzzo E, Guerra JG, Benavente L, Palomino JC, Carrillo C, Lopera J, et al. Use of norfloxacin to treat chronic typhoid carriers. *J Infect Dis* [Internet]. 1988;157(6):1221–5. Available from: <http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed4&NEWS=N&AN=18164987>
30. C. F, J.G. MJ, C. V, I. P, V. S, G.L. D, et al. Efficacy of ciprofloxacin in the treatment of chronic typhoid carriers. *J Infect Dis* [Internet]. 1988;157(6):1235–9. Available from: <http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed4&NEWS=N&AN=18164989>
31. C.M. N, Nolan CM, White PC. Treatment of typhoid carriers with amoxicillin. Correlates of successful therapy. *J Am Med Assoc* [Internet]. 1978;239(22):2352–4. Available from: <http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed2&NEWS=N&AN=8388271>
32. Simon HJ, Miller RC. Ampicillin in the treatment of chronic typhoid carriers. Report on fifteen treated cases and a review of the literature. *N Engl J Med* [Internet]. 1966;274(15):807–15. Available from: <http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med1&NEWS=N&AN=5908876>
33. Ames WR, Robins M. Age and Sex as Factors in the Development of the Typhoid Carrier State, and a Method for Estimating Carrier Prevalence. *Am J Public Heal Nations Heal.* 1943;
34. Treatment of chronic typhoid carriers with ampicillin. *JAMA (Chicago, Ill)* [Internet]. 1971;217(7):913–5. Available from: <http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emcl1&NEWS=N&AN=292051214>
35. C. F, J.G. MJ, C. V, I. P, V. S, G.L. D. Efficacy of ciprofloxacin in the treatment of chronic typhoid carriers. *J Infect Dis* [Internet]. 1988;157(6):1235–9. Available from: <http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed4&NEWS=N&AN=18164989>
36. Nolan CM, White PC. Treatment of Typhoid Carriers With Amoxicillin: Correlates of Successful Therapy. *JAMA J Am Med Assoc.* 1978;

- 751 37. H. P, H. K, K.H. S, G. V. Treatment of chronic carriers of Salmonella typhi
752 and Salmonella paratyphi B with trimethoprim sulfamethoxazole. J Infect
753 Dis. 1973;
- 754 38. Tauchnitz C, Horn M, Forster E. [Treatment of S. typhi and S. paratyphi B
755 carriers]. Zur Sanierung von Typhus- und Paratyphus-B-
756 Dauerausscheidern [Internet]. 1972;27(15):647–54. Available from:
757 [http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med1&NE](http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med1&NEWS=N&AN=4485581)
758 [WS=N&AN=4485581](http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med1&NEWS=N&AN=4485581)
- 759 39. Brodie J, Macqueen IA, Livingstone D. Effect of Trimethoprim-
760 Sulphamethoxazole on Typhoid and Salmonella Carriers. Br Med J. 1970;
- 761 40. CROCKER TT, GELPERIN A, Th.T. C. Treatment of the typhoid carrier state
762 with chloramphenicol. Yale J Biol Med [Internet]. 1950;23(2):119–24.
763 Available from:
764 [http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emcl1&N](http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emcl1&NEWS=N&AN=280603709)
765 [EWS=N&AN=280603709](http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emcl1&NEWS=N&AN=280603709)
- 766 41. C.A. R, RUMBULL CA, MOORE LG, C.A. R, RUMBALL CA, MOORE LG, et al.
767 Treatment of a chronic typhoid carrier with chloromycetin. Br Med J
768 [Internet]. 1949;1(4612):943. Available from:
769 [http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed1&N](http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed1&NEWS=N&AN=608414974)
770 [EWS=N&AN=608414974](http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed1&NEWS=N&AN=608414974)
- 771 42. T.E. W, J.E. S, WOODWARD TE, SMADEL JE, LEY HLJ, T.E. W, et al.
772 Chloramphenicol and other antibiotics in the treatment of typhoid fever
773 and typhoid carriers. J Clin Invest [Internet]. 1950;29(1):87–99. Available
774 from:
775 [http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med1&NE](http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med1&NEWS=N&AN=15399518)
776 [WS=N&AN=15399518](http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med1&NEWS=N&AN=15399518)
- 777 43. A.M. G, R.N. P. Treatment and follow-up studies with co-trimoxazole in
778 enteric fever and in typhoid carriers. J Antimicrob Chemother [Internet].
779 1975;1(1):51–4. Available from:
780 [http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed2&N](http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed2&NEWS=N&AN=5551869)
781 [EWS=N&AN=5551869](http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed2&NEWS=N&AN=5551869)
- 782 44. Dong B-Q, Yang J, Wang X-Y, Gong J, von Seidlein L, Wang M-L, et al. Trends
783 and disease burden of enteric fever in Guangxi province, China, 1994–
784 2004. Bull World Health Organ. 2010;
- 785 45. BOKKENHEUSER V. DETECTION OF TYPHOID CARRIERS. American
786 journal of public health and the nation's health. 1964.
- 787 46. Nath G, Maurya P, Gulati AK, Singh TB, Srivastava R, Kumar K, et al.
788 Comparison of Vi serology and nested PCR in diagnosis of chronic typhoid
789 carriers in two different study populations in typhoid endemic area of
790 India. Southeast Asian J Trop Med Public Health. 2010;
- 791 47. Gupta A, My Thanh NT, Olsen SJ, Sivapalasingam S, My Trinh TT, Phuong
792 Lan NT, et al. Evaluation of community-based serologic screening for
793 identification of chronic Salmonella Typhi carriers in Vietnam. Int J Infect
794 Dis. 2006 Jul 1;10(4):309–14.
- 795 48. Charles RC, Sultana T, Alam MM, Yu Y, Wu-Freeman Y, Bufano MK, et al.
796 Identification of Immunogenic Salmonella enterica Serotype Typhi
797 Antigens Expressed in Chronic Biliary Carriers of S. Typhi in Kathmandu,
798 Nepal. PLoS Negl Trop Dis [Internet]. 2013 [cited 2021 Mar 29];7(8).
799 Available from: <https://pubmed.ncbi.nlm.nih.gov/23936575/>

- 800 49. Franklin F, Chong CW, Chua LH, Anthony AA, Liew MWO, Aziah I, et al.
801 Evaluation of Salmonella Typhi antigen YncE alongside HlyE for the
802 detection of typhoid fever and its carriers. *Med Microbiol Immunol*. 2020;
- 803 50. D. C, J. M, D. K, C.M. H, J.L. S, J.A. K, et al. Drug resistance in Salmonella
804 enterica serotype Typhi isolated from chronic typhoid carriers. *Clin Infect*
805 *Dis [Internet]*. 2015;12(1):536–8. Available from:
806 <http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed1&N>
807 [EWS=N&AN=4495214](http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed1&N)
- 808 51. P. R, F.-X. W, C. D, S. BBB, S. BBB, T.C. N, et al. Evolutionary history of
809 Salmonella Typhi. *Science (80-) [Internet]*. 2006;314(5803):1301–4.
810 Available from: <http://www.sciencemag.org>
- 811 52. Gilbert Davi, Chambers Henry, Saag Michael PA. Sanford Guide to
812 Antimicrobial Therapy 2020. Sanford Guide to Antimicrobial Therapy
813 2020. 2020.
- 814 53. Effa EE, Bukirwa H. Azithromycin for treating uncomplicated typhoid and
815 paratyphoid fever (enteric fever) [Internet]. *Cochrane Database of*
816 *Systematic Reviews*. John Wiley and Sons Ltd; 2008 [cited 2021 Mar 29].
817 Available from: <https://pubmed.ncbi.nlm.nih.gov/18843701/>
- 818 54. Imbert P, Rapp C, Lecoules S, Garrabe E, Debord T. Eradication of
819 multiresistant Salmonella Hadar convalescent-phase carriage with
820 azithromycin. *Clin Microbiol Infect*. 2003 Nov;9(11):1155–6.
- 821 55. Gonzalez-Escobedo G, Marshall JM, Gunn JS, G. G-E, J.M. M, Gonzalez-
822 Escobedo G, et al. Chronic and acute infection of the gall bladder by
823 Salmonella Typhi: Understanding the carrier state. *Nat Rev Microbiol*
824 [Internet]. 2011;9(1):9–14. Available from:
825 <http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed12&>
826 [NEWS=N&AN=51172587](http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed12&)
- 827 56. Vogelsang TM. The campaign against typhoid and paratyphoid B in
828 western Norway. Results of cholecystectomy. *J Hyg (Lond)*. 1964;
- 829 57. Main RG. Treatment of the chronic alimentary enteric carrier. *Br Med J*.
830 1961;
- 831 58. Nath G, Pratap CB, Patel SK, Gulati AK, Tripathi SK. Isolation of Salmonella
832 typhi from apparently healthy liver. *Infect Genet Evol*. 2011;
- 833 59. J. M, D. K, C.M. H, J.L. S, J.A. K, J.R. F, et al. Identification of a Small Molecule
834 Anti-biofilm Agent Against Salmonella enterica. *Front Microbiol [Internet]*.
835 2018;9(NOV):2804. Available from:
836 <http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed12&>
837 [WS=N&AN=30515144](http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed12&)
- 838 60. Prouty AM, Schwesinger WH, Gunn JS, A.M. P, W.H. S, Prouty AM, et al.
839 Biofilm formation and interaction with the surfaces of gallstones by
840 Salmonella spp. *Infect Immun [Internet]*. 2002;70(5):2640–9. Available
841 from:
842 <http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed7&N>
843 [EWS=N&AN=34408410](http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed7&N)
- 844 61. Crawford RW, Rosales-Reyes R, Ramírez-Aguilar MDLL, Chapa-Azuela O,
845 Alpuche-Aranda C, Gunn JS. Gallstones play a significant role in Salmonella
846 spp. gallbladder colonization and carriage. *Proc Natl Acad Sci U S A*. 2010;
- 847 62. J.F. G, H. A, J. L, L. D, Gonzalez JF, Alberts H, et al. Biofilm Formation
848 Protects Salmonella from the Antibiotic Ciprofloxacin In Vitro and In Vivo

849 in the Mouse Model of chronic Carriage. Sci Rep [Internet]. 2018;8(1):222.
850 Available from:
851 <http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med15&N>
852 [EWS=N&AN=29317704](http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med15&N)
853 63. Adcox HE, Vasicek EM, Dwivedi V, Hoang K V, Turner J, Gunn JS, et al.
854 Salmonella extracellular matrix components influence biofilm formation
855 and gallbladder colonization. Infect Immun [Internet]. 2016;84(11):3243–
856 51. Available from:
857 <http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med13&N>
858 [EWS=N&AN=27600501](http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med13&N)
859 64. Persson R, Jick S. Clinical implications of the association between
860 fluoroquinolones and tendon rupture: The magnitude of the effect with
861 and without corticosteroids. Br J Clin Pharmacol. 2019;
862 65. Raine J. Fluoroquinolone antibiotics: New restrictions and precautions due
863 to very rare reports of disabling and potentially long-lasting or irreversible
864 side effects. Medicines & Healthcare products Regulatory Agency. 2019.
865
866

867 **Supporting Information**

869 **S1. PRISMA Checklist**

870 **S2. Search strategy**

871 **S3. Protocol**

872 **S4. R script for comparison of categorical variables**

873

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit www.prisma-statement.org.